In line, rosiglitazone (Avandia, GlaxoSmithKline) – a thiazolidinedione – could both reduce hepatic fibrosis in mice by downregulation of the protein expression of α-SMA, TGF-β1, and CTGF and re-establish the expression of PPARγ (Nan et al., 2009). The gene discussed is CCN2; the disease is Hepatic fibrosis.